Mycobacterium tuberculosis

Co-Diagnostics, Inc. JV CoSara Receives Clearance from Indian Regulators for Influenza Multiplex PCR Test

Retrieved on: 
Thursday, March 7, 2024

SALT LAKE CITY, March 7, 2024 /PRNewswire/ -- Co-Diagnostics, Inc. (Nasdaq: CODX) (the "Company" or "Co-Dx"), a molecular diagnostics company with a unique, patented platform for the development of molecular diagnostic tests, announced today that CoSara Diagnostics Pvt Ltd ("CoSara," or the "JV"), its joint venture for manufacturing and sales in India, has received clearance by the Central Drugs Standard Control Organization ("CDSCO") in India to manufacture and sell its SARAPLEX™ Influenza Multiplex (IFM) Test Kit to clinical laboratories as an in vitro diagnostic ("IVD") for the detection and differentiation of Influenza A and Influenza B.

Key Points: 
  • Co-Primers utilize a unique design architecture to combat common issues with real-time PCR that can lead to inaccurate results, specifically primer dimer propagation, and which are magnified in multiplex reactions.
  • "The importance of accurate, reliable PCR testing at the high-throughput clinical laboratory level remains critical," remarked Dwight Egan, CEO of Co-Diagnostics.
  • *The Co-Dx PCR platform (including the PCR Home™, PCR Pro™, mobile app, and all associated tests) is subject to review by the FDA and/or other regulatory bodies and is not yet available for sale.
  • The Co-Dx PCR Pro instrument and Co-Dx COVID-19 Test are currently under review by the FDA.

Xtalks Announces its Life Science Webinar Calendar for March 2024

Retrieved on: 
Friday, March 1, 2024

TORONTO, March 1, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries. Access to all webinars is free, so be sure to register today to save your place! Participate in the discussion and stay relevant in your field!

Key Points: 
  • TORONTO, March 1, 2024 /PRNewswire-PRWeb/ -- Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.
  • Access to all webinars is free, so be sure to register today to save your place!
  • Participate in the discussion and stay relevant in your field!
  • Stay on top of current hot topics through free webinars presented by leading experts in the pharma, biotech, medical device and food industries.

Droplet-based Whole Genome Amplification: Successfully Sequencing Minute Amounts of Mycobacterium Tuberculosis DNA, Upcoming Webinar Hosted by Xtalks

Retrieved on: 
Wednesday, February 28, 2024

TORONTO, Feb. 28, 2024 /PRNewswire-PRWeb/ -- Whole genome sequencing (WGS) is crucial for tuberculosis (TB) surveillance, but its implementation in patient care is hindered by the limited amount of Mycobacterium tuberculosis (Mtb) in clinical specimens and the slow growth of Mtb.

Key Points: 
  • In this free webinar, delve into the significance of whole genome sequencing (WGS) in advancing tuberculosis (TB) surveillance.
  • Attendees will learn how droplet-based multiple displacement amplification (dMDA) coupled with WGS helped successfully sequence minute amounts of Mtb DNA.
  • The control and 5 pg input dMDA samples underwent nanopore sequencing and were analysed using nanorate sequencing (Nanoseq) and TB-profiler.
  • Register for this webinar today to gain insights into how dMDA amplification coupled with whole genome sequencing helped successfully sequence minute amounts of Mtb DNA.

Thermo Fisher Scientific Introduces New Sample Preparation Solutions to Simplify and Automate Respiratory Diagnostic Testing

Retrieved on: 
Monday, December 11, 2023

Together these products provide laboratories with an in vitro diagnostic (IVD) and in vitro diagnostic regulation (IVD-R) approved automated sample preparation solutions for increased confidence in downstream results.

Key Points: 
  • Together these products provide laboratories with an in vitro diagnostic (IVD) and in vitro diagnostic regulation (IVD-R) approved automated sample preparation solutions for increased confidence in downstream results.
  • Clinical laboratories that perform respiratory testing need to generate the highest quality results.
  • “The KingFisher Apex Dx system builds on decades of product expertise and innovation customers have come to trust in our KingFisher instrument line,” said Ellie Mahjubi, vice president and general manager, sample preparation at Thermo Fisher Scientific.
  • For more information including technical specifications, applications, and consumables, please visit www.thermofisher.com/kingfisherapex and MagMAX Dx Viral/Pathogen Nucleic Acid Isolation Kit.

Longhorn Vaccines and Diagnostics Presents Targeted Vaccine Approach for Mycobacterium Tuberculosis with LHNVD-301

Retrieved on: 
Wednesday, November 15, 2023

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, today presented new data from an animal study of LHNVD-301, the company’s lead tuberculosis vaccine candidate.
  • The data showed that a mycobacterium tuberculosis (MTB) vaccine could generate broader protection against other pathogens susceptible to antimicrobial resistance (AMR).
  • LHNVD-301 is an unconjugated, peptide-based vaccine that combines a MTB heat shock protein epitope and a peptidoglycan (PGN) epitope.
  • It represents a novel approach that combats AMR, while targeting tuberculosis by combining multiple epitopes specific to MTB and common to gram-positive bacteria into a peptide vaccine.

Longhorn Vaccines and Diagnostics to Present Data on Mycobacterium Tuberculosis Vaccine Candidate, LHNVD-301, at The Union World Conference on Lung Health 2023

Retrieved on: 
Thursday, November 2, 2023

Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.

Key Points: 
  • Longhorn Vaccines and Diagnostics , a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, will present new data from an animal study of LHNVD-301, the company’s tuberculosis vaccine candidate, at The Union World Conference on Lung Health 2023.
  • The ePoster will be presented as a part of TBScience 2023, a dedicated event focused on basic and translational tuberculosis (TB) research.
  • LHNVD-301 is an unconjugated, peptide-based vaccine that combines Mycobacterium tuberculosis heat shock protein and Peptidoglycan to generate broad reactive antibodies.
  • ePoster Session Title: TB within the Global AMR fight: preventing drug resistance
    Over the last 53 years, the Union World Conference on Lung Health has presented the latest scientific research in all aspects of lung health, including implementation of evidence-based health policies and decisions.

Tuberculosis isn't just a historical disease. Here's how it spreads and who is at risk

Retrieved on: 
Tuesday, October 17, 2023

Tuberculosis is often seen as a threat of the past. But it remains a significant concern worldwide, with international travel spreading the disease. While tuberculous is rare in Australia, and we no longer routinely vaccinate against it, clusters of cases in South Australia over the past 17 months have put health authorities on alert. So what exactly is tuberculosis, how is it treated and what is Australia doing to prevent its transmission? It starts as a respiratory infection Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, starts as a respiratory infection when inhaled.

Key Points: 


Tuberculosis is often seen as a threat of the past. But it remains a significant concern worldwide, with international travel spreading the disease. While tuberculous is rare in Australia, and we no longer routinely vaccinate against it, clusters of cases in South Australia over the past 17 months have put health authorities on alert. So what exactly is tuberculosis, how is it treated and what is Australia doing to prevent its transmission?

It starts as a respiratory infection

    • Tuberculosis, caused by the bacterium Mycobacterium tuberculosis, starts as a respiratory infection when inhaled.
    • Once in the lungs, the immune system responds by forming granulomas, clusters of immune cells (mainly macrophages and T cells), in an attempt to contain the infection.

Early treatment is key

    • Early diagnosis and treatment reduces the infectious period and helps prevent spreading the disease to others.
    • Delayed treatment can lead to complications such as lung damage and scarring; damage to the bones, kidneys, lymph nodes and central nervous system; and infection in the brain and spinal cord.
    • Antibiotic treatment, often involving multiple drugs, is highly effective at eliminating the bacteria.

Tackling drug-resistant bacteria

    • The Mycobacterium tuberculosis bacteria can quickly become resistant to antibiotics, so routine treatment includes multiple antibiotics which increases adverse effects.
    • The emergence of drug-resistant tuberculosis strains is a major concern because it makes treatment significantly more challenging and costly.

Who is susceptible to tuberculosis?

    • Children are also at greater risk of tuberculosis, as their immune systems are still developing.
    • However, the World Health Organization estimates 11% of the 10.6 million tuberculosis cases worldwide are in children.
    • Some 14% of all tuberculosis-related deaths occur in children under 15 years old.

What can we do about TB?

    • The Bacille Calmette-Guérin vaccine provides partial protection, primarily against severe forms of tuberculosis.
    • It’s not routinely given in Australia because we’re not considered a high-risk country, but it’s given in local regions with tuberculosis outbreaks.
    • Visa applicants aged 11 years and over must have a chest X-ray for evidence of active tuberculosis.

Avalon’s Laboratory Services MSO Launches Innovative Laboratory Test for Tuberculosis

Retrieved on: 
Wednesday, August 30, 2023

FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house laboratory developed test (“LDT”) to detect Tuberculosis (“TB”) using a patient’s sputum sample. Avalon owns a 40% interest in LSM.

Key Points: 
  • FREEHOLD, N.J., Aug. 30, 2023 (GLOBE NEWSWIRE) -- Avalon GloboCare Corp. (“Avalon” or the “Company”) (NASDAQ: ALBT), a developer of innovative precision diagnostics and provider of clinical laboratory services, today announced that Laboratory Services MSO, LLC (“LSM”) is now offering an in-house laboratory developed test (“LDT”) to detect Tuberculosis (“TB”) using a patient’s sputum sample.
  • LSM’s new polymerase chain reaction (“PCR”) test allows for accurate and rapid identification of Mycobacterium tuberculosis (“Mtb”) from samples.
  • The most frequently used diagnostic methods for tuberculosis are the tuberculin skin test, acid-fast stain, culture, and polymerase chain reaction.
  • This test also has a significantly higher throughput and much lower cost per test as compared to the standard diagnostic tests.

ISB Researchers Find a Chink in the Armor of Tuberculosis Pathogen

Retrieved on: 
Tuesday, August 29, 2023

Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease.

Key Points: 
  • Mycobacterium tuberculosis (Mtb) is the pathogen that causes tuberculosis (TB), the world’s deadliest infectious disease.
  • Mtb is so successful and harmful because it can adapt to different conditions inside our bodies, allowing it to evade treatment.
  • When the network is disrupted, researchers found that Mtb’s cells are unable to properly divide, compromising their cell wall – a key defense mechanism.
  • EGRIN 2.0 identified a signaling system called MtrA that helps the pathogen grow in response to signals from a host’s body.

New Study Shows Longhorn Vaccines and Diagnostics’ PrimeStore Molecular Transport Medium Improves Tuberculosis Testing in Children

Retrieved on: 
Tuesday, August 22, 2023

The data were published in a recent edition of the peer-reviewed International Journal of Tuberculosis and Lung Disease (IJTLD).

Key Points: 
  • The data were published in a recent edition of the peer-reviewed International Journal of Tuberculosis and Lung Disease (IJTLD).
  • Globally, an estimated one million children develop TB annually, mostly in low-income countries.
  • Testing is essential to early interventional treatment, so the use of stool swabs in molecular transport media was examined as a non-invasive, cost-effective and safe testing method.
  • PS-MTM inactivates TB and stabilizes DNA without refrigerated sample transport, which eliminates the need for cold-chain transport and storage.